Browse SPI1

Summary
SymbolSPI1
NameSpi-1 proto-oncogene
Aliases PU.1; SPI-A; SFPI1; SPI-1; hematopoietic transcription factor PU.1; 31 kDa transforming protein; spleen focu ......
Chromosomal Location11p12-p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00178 Ets-domain
Function

Binds to the PU-box, a purine-rich DNA sequence (5'-GAGGAA-3') that can act as a lymphoid-specific enhancer. This protein is a transcriptional activator that may be specifically involved in the differentiation or activation of macrophages or B-cells. Also binds RNA and may modulate pre-mRNA splicing (By similarity).

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001569 patterning of blood vessels
GO:0001763 morphogenesis of a branching structure
GO:0001773 myeloid dendritic cell activation
GO:0002244 hematopoietic progenitor cell differentiation
GO:0002262 myeloid cell homeostasis
GO:0002274 myeloid leukocyte activation
GO:0002320 lymphoid progenitor cell differentiation
GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0006304 DNA modification
GO:0006305 DNA alkylation
GO:0006306 DNA methylation
GO:0006473 protein acetylation
GO:0006475 internal protein amino acid acetylation
GO:0007389 pattern specification process
GO:0016570 histone modification
GO:0016573 histone acetylation
GO:0018205 peptidyl-lysine modification
GO:0018393 internal peptidyl-lysine acetylation
GO:0018394 peptidyl-lysine acetylation
GO:0019827 stem cell population maintenance
GO:0030098 lymphocyte differentiation
GO:0030099 myeloid cell differentiation
GO:0030218 erythrocyte differentiation
GO:0030225 macrophage differentiation
GO:0030851 granulocyte differentiation
GO:0031056 regulation of histone modification
GO:0031057 negative regulation of histone modification
GO:0032259 methylation
GO:0032844 regulation of homeostatic process
GO:0034101 erythrocyte homeostasis
GO:0035019 somatic stem cell population maintenance
GO:0035065 regulation of histone acetylation
GO:0035067 negative regulation of histone acetylation
GO:0035239 tube morphogenesis
GO:0040029 regulation of gene expression, epigenetic
GO:0043011 myeloid dendritic cell differentiation
GO:0043414 macromolecule methylation
GO:0043543 protein acylation
GO:0043966 histone H3 acetylation
GO:0043967 histone H4 acetylation
GO:0044026 DNA hypermethylation
GO:0044027 hypermethylation of CpG island
GO:0044030 regulation of DNA methylation
GO:0044728 DNA methylation or demethylation
GO:0045342 MHC class II biosynthetic process
GO:0045346 regulation of MHC class II biosynthetic process
GO:0045347 negative regulation of MHC class II biosynthetic process
GO:0045471 response to ethanol
GO:0045637 regulation of myeloid cell differentiation
GO:0045646 regulation of erythrocyte differentiation
GO:0045814 negative regulation of gene expression, epigenetic
GO:0048514 blood vessel morphogenesis
GO:0048754 branching morphogenesis of an epithelial tube
GO:0048872 homeostasis of number of cells
GO:0051052 regulation of DNA metabolic process
GO:0060033 anatomical structure regression
GO:0060561 apoptotic process involved in morphogenesis
GO:0060562 epithelial tube morphogenesis
GO:0061138 morphogenesis of a branching epithelium
GO:0061614 pri-miRNA transcription from RNA polymerase II promoter
GO:0071361 cellular response to ethanol
GO:0090239 regulation of histone H4 acetylation
GO:0090241 negative regulation of histone H4 acetylation
GO:0097028 dendritic cell differentiation
GO:0097305 response to alcohol
GO:0097306 cellular response to alcohol
GO:0098727 maintenance of cell number
GO:1901983 regulation of protein acetylation
GO:1901984 negative regulation of protein acetylation
GO:1902262 apoptotic process involved in patterning of blood vessels
GO:1902275 regulation of chromatin organization
GO:1902742 apoptotic process involved in development
GO:1902893 regulation of pri-miRNA transcription from RNA polymerase II promoter
GO:1902895 positive regulation of pri-miRNA transcription from RNA polymerase II promoter
GO:1903706 regulation of hemopoiesis
GO:1905268 negative regulation of chromatin organization
GO:2000756 regulation of peptidyl-lysine acetylation
GO:2000757 negative regulation of peptidyl-lysine acetylation
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000979 RNA polymerase II core promoter sequence-specific DNA binding
GO:0000980 RNA polymerase II distal enhancer sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001046 core promoter sequence-specific DNA binding
GO:0001047 core promoter binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001078 transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001085 RNA polymerase II transcription factor binding
GO:0001158 enhancer sequence-specific DNA binding
GO:0001159 core promoter proximal region DNA binding
GO:0001205 transcriptional activator activity, RNA polymerase II distal enhancer sequence-specific binding
GO:0001227 transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003705 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding
GO:0008134 transcription factor binding
GO:0035326 enhancer binding
GO:0051525 NFAT protein binding
Cellular Component GO:0000785 chromatin
GO:0000790 nuclear chromatin
GO:0044454 nuclear chromosome part
> KEGG and Reactome Pathway
 
KEGG hsa04380 Osteoclast differentiation
Reactome -
Summary
SymbolSPI1
NameSpi-1 proto-oncogene
Aliases PU.1; SPI-A; SFPI1; SPI-1; hematopoietic transcription factor PU.1; 31 kDa transforming protein; spleen focu ......
Chromosomal Location11p12-p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SPI1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between SPI1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23770850Acute Promyelocytic Leukemia with PML-RARAInhibit immunityIt has been established that impairment of the immunoproteasome subunits, that is, PSMB8, PSMB9 and PSMB10 (PSMBs), is critical for malignant cells to escape immune recognition. We report here the regulatory mechanism of the repression of PU.1-dependent activation of PSMBs by PML/RARĪ± in the pathogenesis of acute promyelocytic leukemia (APL) and the unidentified function of all-trans retinoic acid (ATRA) as an immunomodulator in the treatment of APL. Collectively, our data demonstrate that PML/RARĪ± suppresses PU.1-dependent activation of the immunosubunits, which may facilitate the escape of APL cells from immune surveillance in leukemia development, and ATRA treatment is able to reactivate their expression, which would promote more efficient T-cell-mediated recognition in the treatment.
Summary
SymbolSPI1
NameSpi-1 proto-oncogene
Aliases PU.1; SPI-A; SFPI1; SPI-1; hematopoietic transcription factor PU.1; 31 kDa transforming protein; spleen focu ......
Chromosomal Location11p12-p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SPI1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSPI1
NameSpi-1 proto-oncogene
Aliases PU.1; SPI-A; SFPI1; SPI-1; hematopoietic transcription factor PU.1; 31 kDa transforming protein; spleen focu ......
Chromosomal Location11p12-p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SPI1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0970.824
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2340.92
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0011
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0790.895
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4170.801
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.7210.767
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1540.756
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3220.787
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0840.951
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.3050.467
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9630.732
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1560.38
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SPI1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSPI1
NameSpi-1 proto-oncogene
Aliases PU.1; SPI-A; SFPI1; SPI-1; hematopoietic transcription factor PU.1; 31 kDa transforming protein; spleen focu ......
Chromosomal Location11p12-p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SPI1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSPI1
NameSpi-1 proto-oncogene
Aliases PU.1; SPI-A; SFPI1; SPI-1; hematopoietic transcription factor PU.1; 31 kDa transforming protein; spleen focu ......
Chromosomal Location11p12-p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SPI1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SPI1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSPI1
NameSpi-1 proto-oncogene
Aliases PU.1; SPI-A; SFPI1; SPI-1; hematopoietic transcription factor PU.1; 31 kDa transforming protein; spleen focu ......
Chromosomal Location11p12-p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SPI1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSPI1
NameSpi-1 proto-oncogene
Aliases PU.1; SPI-A; SFPI1; SPI-1; hematopoietic transcription factor PU.1; 31 kDa transforming protein; spleen focu ......
Chromosomal Location11p12-p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SPI1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSPI1
NameSpi-1 proto-oncogene
Aliases PU.1; SPI-A; SFPI1; SPI-1; hematopoietic transcription factor PU.1; 31 kDa transforming protein; spleen focu ......
Chromosomal Location11p12-p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SPI1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSPI1
NameSpi-1 proto-oncogene
Aliases PU.1; SPI-A; SFPI1; SPI-1; hematopoietic transcription factor PU.1; 31 kDa transforming protein; spleen focu ......
Chromosomal Location11p12-p11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SPI1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.